Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Actinium Pharmaceuticals, Inc. (ATNM) vs Karyopharm Therapeutics Inc. (KPTI)

Actinium Pharmaceuticals, Inc. and Karyopharm Therapeutics Inc. are both Biotechnology companies. Actinium Pharmaceuticals, Inc. and Karyopharm Therapeutics Inc. are of similar size ($39.2M and $37.4M). Karyopharm Therapeutics Inc. has negative trailing earnings, so its P/E is not meaningful; Actinium Pharmaceuticals, Inc. trades at 3.3×. Actinium Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 2,731.2% against 6.81%. Actinium Pharmaceuticals, Inc. has the higher net margin (32.2% vs −153.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Actinium Pharmaceuticals, Inc. leads on 10 and Karyopharm Therapeutics Inc. on 5.

Valuation

Metric ATNM KPTI Biotechnology median
P/E 3.33 n/m 7.88
P/S 1.07 0.32 11.47
P/B 1.24 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.17 n/m 0.74
EV/Sales 0.05 1.58 10.73
Earnings yield 30.00% (874.99%) (28.84%)
Free cash flow yield (61.70%) (139.70%) (23.03%)

Profitability

Metric ATNM KPTI Biotechnology median
Gross margin 98.71% 95.89% 65.16%
Operating margin 27.20% (56.17%) 0.00%
Net margin 32.18% (153.28%) 0.00%
Free cash flow margin (66.16%) (44.57%) 0.00%
Return on equity 45.86% 78.98% (57.72%)
Return on assets 21.92% (207.90%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ATNM KPTI Biotechnology median
Revenue growth (TTM) 2,731.18% 6.81% 5.64%
EPS growth (last fiscal year) 14.17% (98.37%) —
Revenue growth, 5-year CAGR — 6.21% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ATNM KPTI Biotechnology median
Debt to equity 0.00 (0.76) 0.00
Current ratio 4.08 0.79 4.73
Net debt to EBITDA 1.35 (2.03) 0.96

Dividend

Metric ATNM KPTI Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ATNM KPTI Biotechnology median
Market cap 37.42m 39.24m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack